Unnamed: 0,title,date,stock,sentiment
269097.0,98 Biggest Movers From Friday,2020-05-04 05:08:00-04:00,CNCE,neutral
269098.0,"The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1",2020-04-30 07:19:00-04:00,CNCE,positive
269099.0,Concert Pharmaceuticals Q1 EPS $(0.700) Beats $(0.780) Estimate,2020-04-30 07:08:00-04:00,CNCE,neutral
269100.0,"The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight",2020-04-26 16:37:00-04:00,CNCE,negative
269101.0,Concert Pharmaceuticals Announces Plans For CTP-543 Phase 3 Trials In Alopecia Areata,2020-04-01 07:05:00-04:00,CNCE,neutral
269102.0,140 Biggest Movers From Friday,2020-03-02 04:43:00-05:00,CNCE,neutral
269103.0,"Concert Pharmaceuticals Q4 EPS $(0.86) Misses $(0.79) Estimate, Sales $13K Beat $10K Estimate",2020-02-27 08:19:00-05:00,CNCE,negative
269104.0,"The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy",2020-02-27 07:35:00-05:00,CNCE,positive
269105.0,The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace,2020-02-23 18:38:00-05:00,CNCE,neutral
269106.0,Concert Pharma Shares Rebound From Session Low Following Form 4 Filing From Co. Director Thomas Auchincloss Shows Purchase Of 1K Shares Of Co. Stock At Average Of $10.91/Share,2020-02-04 11:33:00-05:00,CNCE,positive
269107.0,70 Biggest Movers From Yesterday,2020-01-29 04:40:00-05:00,CNCE,neutral
269108.0,46 Stocks Moving In Tuesday's Mid-Day Session,2020-01-28 11:50:00-05:00,CNCE,neutral
269109.0,Concert Pharmaceuticals Prices ~4.75M Share Common Stock Offering At $9.92/Share,2020-01-28 09:04:00-05:00,CNCE,positive
269110.0,"The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics",2020-01-28 07:12:00-05:00,CNCE,positive
269111.0,"Concert Pharma Reports Offering, No Size Disclosed",2020-01-27 16:02:00-05:00,CNCE,negative
269112.0,"Concert Pharma Reports Federal Circuit Granted Motion To Vacate, Remand PTAB Decision Involving CTP-543",2020-01-27 16:01:00-05:00,CNCE,positive
269113.0,70 Biggest Movers From Friday,2020-01-27 04:02:00-05:00,CNCE,neutral
269114.0,36 Stocks Moving in Thursday's Pre-Market Session,2020-01-23 07:16:00-05:00,CNCE,neutral
269115.0,70 Biggest Movers From Yesterday,2020-01-23 05:52:00-05:00,CNCE,neutral
269116.0,26 Biotechnology Stocks Moving In Wednesday's After-Market Session,2020-01-22 23:28:00-05:00,CNCE,neutral
269117.0,36 Healthcare Stocks Moving In Wednesday's After-Market Session,2020-01-22 23:23:00-05:00,CNCE,neutral
269118.0,"Concert Pharmaceuticals Announces It Received A Notice of Allowance for U.S. Patent Application Related to CTP-543, Lead Candidate for Treatment of Alopecia Areata",2020-01-22 08:40:00-05:00,CNCE,neutral
269119.0,Concert Pharma Reports Successful Completion Of Open Label Trial Of CTP-543 In Patients With Alopecia Areata,2019-12-19 16:05:00-05:00,CNCE,positive
269120.0,Concert Pharmaceuticals Initiates CTP-692 Phase 2 Trial in Schizophrenia,2019-12-02 07:14:00-05:00,CNCE,neutral
269121.0,74 Biggest Movers From Yesterday,2019-11-13 04:42:00-05:00,CNCE,neutral
269122.0,50 Stocks Moving In Tuesday's Mid-Day Session,2019-11-12 12:12:00-05:00,CNCE,neutral
269123.0,"Concert Pharmaceuticals Q3 EPS $(0.72) Beats $(0.83) Estimate, Sales $10K May Not Compare To $60K Estimate",2019-11-07 08:26:00-05:00,CNCE,neutral
269124.0,"The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs",2019-11-07 07:18:00-05:00,CNCE,negative
269125.0,Concert Pharmaceuticals Presents Positive Phase 2 Data in Alopecia Areata During Late-Breaker Session at EADV 2019,2019-10-12 15:49:00-04:00,CNCE,positive
269126.0,"The Week Ahead In Biotech: Pfenex And Clinuvel On The Radar Ahead of FDA Decisions, 2 IPOs On Deck",2019-10-06 17:15:00-04:00,CNCE,neutral
269127.0,"H.C. Wainwright Reiterates Buy on Concert Pharmaceuticals, Lowers Price Target to $25",2019-10-03 08:05:00-04:00,CNCE,negative
269128.0,"The Daily Biotech Pulse: J&J Settles Ohio Opioid Lawsuit, Teligent Explores Options For Certain Assets, Novartis Reports Cosentyx Data",2019-10-02 07:17:00-04:00,CNCE,positive
269129.0,Concert Pharmaceuticals to Provide Overview of Clinical Pipeline at Cantor Healthcare Conference Oct. 3,2019-10-02 07:09:00-04:00,CNCE,neutral
269130.0,Stocks That Hit 52-Week Lows On Tuesday,2019-10-01 14:35:00-04:00,CNCE,negative
269131.0,"The Daily Biotech Pulse: Safety Scare For Anaptys' Psoriasis Drug, NewLink Genetics To Merge With Lumos, Insider Buy Props Up VBI Vaccines",2019-10-01 08:10:00-04:00,CNCE,negative
269132.0,"SunTrust Robinson Humphrey Maintains Buy on Concert Pharmaceuticals, Lowers Price Target to $20",2019-09-30 09:10:00-04:00,CNCE,negative
269133.0,"Mizuho Maintains Buy on Concert Pharmaceuticals, Lowers Price Target to $18",2019-09-30 07:16:00-04:00,CNCE,negative
269134.0,Hearing Mizuho Has Cut its Price Target on Concert Pharma,2019-09-30 06:37:00-04:00,CNCE,negative
269135.0,52 Biggest Movers From Friday,2019-09-30 03:39:00-04:00,CNCE,neutral
269136.0,34 Stocks Moving In Friday's Mid-Day Session,2019-09-27 12:11:00-04:00,CNCE,neutral
269137.0,Concert Pharma Reports Completion Of Enrollment In Second Open Label Trial Of CTP-543 To Evaluate Once-Daily vs Twice-Daily Dosing In Patients With Alopecia Areata,2019-09-17 07:02:00-04:00,CNCE,neutral
269138.0,"Concert Pharma Highlights CTP-543 Phase 2 Alopecia Areata Data Selected For Late-Breaker Oral Presentation At EADV Congress Oct. 12, 2019",2019-09-12 07:03:00-04:00,CNCE,neutral
269139.0,"The Daily Biotech Pulse: Translate Bio Halts mRNA Therapy Trial, Roche Multiple Sclerosis Biomarker Data, D-Day For Xeris",2019-09-10 07:36:00-04:00,CNCE,neutral
269140.0,"The Week Ahead In Biotech: Conference Presentations, IPO News Flow Take The Spotlight",2019-09-08 11:01:00-04:00,CNCE,neutral
269141.0,60 Biggest Movers From Yesterday,2019-09-05 05:20:00-04:00,CNCE,neutral
269142.0,46 Stocks Moving In Wednesday's Mid-Day Session,2019-09-04 12:27:00-04:00,CNCE,neutral
269143.0,UPDATE: Mizuho On Concert Pharmaceuticals Believes 'the latest data compares favorably to competitors' data and we see potential for CTP-543 to be best-in-class for the treatment of AA',2019-09-04 10:58:00-04:00,CNCE,positive
269144.0,"UPDATE: Mizuho Reiterates Buy On Concert Pharmaceuticals, Raises Target To $29 As Firm Notes Co's 'Strong Data from CTP-543 12mg Dose'; Firm Raises 'probability of success for CTP-543 from 35% to 60%'",2019-09-04 10:58:00-04:00,CNCE,positive
269145.0,"Mizuho Maintains Buy on Concert Pharmaceuticals, Raises Price Target to $29",2019-09-04 06:29:00-04:00,CNCE,neutral
269146.0,66 Biggest Movers From Yesterday,2019-09-04 05:07:00-04:00,CNCE,neutral
269147.0,Concert Pharmaceuticals shares are trading higher after the company's Phase 2 trial of CTP-543 in Alopecia Areata patients met its primary endpoint in both the 8 mg and 12 mg cohorts.,2019-09-03 09:27:00-04:00,CNCE,positive
269148.0,Concert Pharmaceuticals Reports CTP-543 Achieved Primary Endpoint In 8 mg And 12 mg Twice-Daily Dosing Cohorts,2019-09-03 07:00:00-04:00,CNCE,neutral
269149.0,Concert Pharmaceuticals Q2 EPS $(0.78) Beats $(0.89) Estimate,2019-08-01 07:24:00-04:00,CNCE,neutral
269150.0,"The Daily Biotech Pulse: Exelixis Signs Cancer Drug Licensing Deal, Adamis Offering, Surmodics Surges On Earnings",2019-08-01 07:18:00-04:00,CNCE,negative
269151.0,"The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate",2019-07-27 14:32:00-04:00,CNCE,negative
269152.0,60 Biggest Movers From Yesterday,2019-06-25 05:12:00-04:00,CNCE,neutral
269153.0,40 Stocks Moving In Monday's Mid-Day Session,2019-06-24 12:35:00-04:00,CNCE,neutral
269154.0,"Benzinga's Top Upgrades, Downgrades For June 24, 2019",2019-06-24 09:50:00-04:00,CNCE,positive
269155.0,Concert Pharmaceuticals shares are trading higher after SunTrust Robinson Humphrey initiated coverage on the stock with a Buy rating and a price target of $30 per share.,2019-06-24 08:49:00-04:00,CNCE,positive
269156.0,"SunTrust Robinson Humphrey Initiates Coverage On Concert Pharmaceuticals with Buy Rating, Announces $30 Price Target",2019-06-24 07:15:00-04:00,CNCE,neutral
269157.0,"UPDATE: Janney Upgrades Concert Pharma To Buy 'on clinical progress with CTP-692, a program we believe has blockbuster potential that adds a Ph.2-ready program to a portfolio that includes Ph.2 CTP-543 and partnered program, Ph.3 AVP-786 (data 2H19)'",2019-06-13 13:43:00-04:00,CNCE,positive
269158.0,"Benzinga's Top Upgrades, Downgrades For June 13, 2019",2019-06-13 10:32:00-04:00,CNCE,positive
269159.0,Janney Capital Upgrades Concert Pharmaceuticals to Buy,2019-06-13 06:32:00-04:00,CNCE,neutral
269160.0,Concert Pharmaceuticals Reports Results From Phase 1 Studies Evaluating CTP-692 In Healthy Volunteers; Co. Expects To Initiate Phase 2 Trial In Patients With Schizophrenia In Q4,2019-06-12 07:03:00-04:00,CNCE,positive
269161.0,52 Biggest Movers From Yesterday,2019-06-11 04:43:00-04:00,CNCE,neutral
269162.0,Concert Pharmaceuticals Completes Enrollment In Open Label Trial To Evaluate Once-Daily vs. Twice-Daily Dosing Of CTP-543 In Patients With Alopecia Areata,2019-06-05 07:13:00-04:00,CNCE,neutral
269163.0,The Week Ahead In Biotech: ASCO Presentations In The Spotlight,2019-05-26 17:03:00-04:00,CNCE,neutral
269164.0,Concert Pharma Reports Initiation Of New Open Label Trial To Evaluate Once-Daily vs Twice-Daily Dosing Of CTP-543 In Patients With Alopecia Areata,2019-05-16 07:10:00-04:00,CNCE,neutral
269165.0,"The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data",2019-05-02 08:16:00-04:00,CNCE,positive
269166.0,"Concert Pharmaceuticals Q1 EPS $(0.93) Misses $(0.62) Estimate, Sales $1.005M Miss $5.35M Estimate",2019-05-02 07:57:00-04:00,CNCE,negative
269167.0,"The Daily Biotech Pulse: Adverum Gets New CFO, Flexion's Osteoarthritis Trial, Bristol-Myers Earnings",2019-04-25 07:58:00-04:00,CNCE,neutral
269168.0,"The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs",2019-04-21 14:06:00-04:00,CNCE,neutral
269169.0,"The Daily Biotech Pulse: Merck's Keytruda Clinches Another FDA Win, KemPharm Close To NDA Filing For ADHD Drug",2019-04-12 07:47:00-04:00,CNCE,positive
269170.0,Shares of several healthcare companies are trading lower. Not seeing any immediate news to explain price action.,2019-04-11 13:47:00-04:00,CNCE,neutral
269171.0,Concert Pharmaceuticals Initiates Phase 1 Multiple-Ascending Dose Trial Of CTP-692 As Adjunctive Treatment For Schizophrenia,2019-04-10 06:30:00-04:00,CNCE,neutral
269172.0,"Stifel Nicolaus Maintains Buy on Concert Pharmaceuticals, Lowers Price Target to $18",2019-04-09 11:06:00-04:00,CNCE,negative
269173.0,50 Biggest Movers From Yesterday,2019-04-09 06:48:00-04:00,CNCE,neutral
269174.0,Concert Pharmaceuticals Comments On Decision From Patent Trial and Appeal Board In IPR Proceeding; Says Decision Does Not Affect Other Programs In Portfolio,2019-04-08 14:47:00-04:00,CNCE,neutral
269175.0,Concert Pharmaceuticals shares are trading lower after the company lost an IPR patent. The PTAB ruled that Incyte proved Concert's '149 patent claims were unpatentable.,2019-04-08 14:17:00-04:00,CNCE,negative
269176.0,"Concert Pharmaceuticals Shares Resume Trade, Down 20.8%",2019-04-08 14:12:00-04:00,CNCE,positive
269177.0,Concert Pharmaceuticals Shares Halted On Circuit Breaker,2019-04-08 14:07:00-04:00,CNCE,positive
269178.0,Concert Pharmaceuticals Loses IPR Patent Trial As PTAB Rules Incyte Proved That Concert '149 Patent Claims Are Unpatentable,2019-04-08 14:06:00-04:00,CNCE,negative
269179.0,54 Biggest Movers From Yesterday,2019-04-03 05:42:00-04:00,CNCE,neutral
269180.0,60 Biggest Movers From Friday,2019-03-25 05:42:00-04:00,CNCE,neutral
269181.0,Concert Pharmaceuticals To Present At Oppenheimer Healthcare Conference,2019-03-12 07:11:00-04:00,CNCE,neutral
269182.0,Concert Pharmaceuticals Announces Initiation Of Open Label Trial To Evaluate Once-Daily vs Twice-Daily Dosing Of CTP-543 In Patients With Alopecia Areata,2019-03-06 07:03:00-05:00,CNCE,neutral
269183.0,Concert Pharma Presents Interim CTP-543 Phase 2 Data in Alopecia Areata during Late-Breaker Session at American Academy of Dermatology Annual Meeting: Showed Statistically Significant Effect on Primary Endpoint,2019-03-01 07:07:00-05:00,CNCE,positive
269184.0,"The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems",2019-02-28 08:24:00-05:00,CNCE,positive
269185.0,"Concert Pharmaceuticals Q4 EPS $(0.89) Misses $(0.74) Estimate, Sales $13K Up From $12K YoY",2019-02-28 07:09:00-05:00,CNCE,negative
269186.0,Concert Pharmaceuticals Selected for Late-Breaking Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata at 2019 AAD Annual Meeting,2019-02-11 07:07:00-05:00,CNCE,neutral
269187.0,Concert Pharma Initiate Phase 1 Single-Ascending Dose Trial of CTP-692 as an Adjunctive Treatment for Schizophrenia,2019-01-24 07:05:00-05:00,CNCE,neutral
269188.0,Concert Pharmaceuticals Completes Enrollment Of 12 Mg Cohort In Phase 2a Trial Of Ctp-543 In Alopecia Areata,2019-01-22 07:02:00-05:00,CNCE,neutral
269189.0,UPDATE: Mizuho On Concert Pharma Notes Early Competitor Data From Aclaris Therapeutics' Topical JAK 1/3 Treatment Of Alopecia Areata Failed To Impress,2018-12-18 10:56:00-05:00,CNCE,negative
269190.0,"Mizuho Reiterates Buy, $26 Target On Concert Pharma, Calls CTP-543 'best-in-class for the treatment of moderate/severe AA'",2018-12-18 10:55:00-05:00,CNCE,neutral
269191.0,Concert Pharmaceuticals Initiates Phase 1 Clinical Program of CTP-692 for the Treatment of Schizophrenia,2018-12-17 07:05:00-05:00,CNCE,neutral
269192.0,55 Biggest Movers From Friday,2018-11-19 05:53:00-05:00,CNCE,neutral
269193.0,48 Stocks Moving In Friday's Mid-Day Session,2018-11-16 13:15:00-05:00,CNCE,neutral
269194.0,"The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results",2018-11-15 08:10:00-05:00,CNCE,positive
269195.0,"The Daily Biotech Pulse: Mallinckrodt Faces FDA Panel, Reshape's Earnings, Vapotherm To Debut",2018-11-14 08:17:00-05:00,CNCE,neutral
269196.0,70 Biggest Movers From Yesterday,2018-11-13 04:46:00-05:00,CNCE,neutral
269197.0,Concert Pharma's CTP-543 Achieved its Primary Endpoint in the 8 mg Twice-Daily Cohort,2018-11-12 07:03:00-05:00,CNCE,neutral
269198.0,52 Biggest Movers From Yesterday,2018-11-06 05:52:00-05:00,CNCE,neutral
269199.0,"The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal",2018-11-01 07:30:00-04:00,CNCE,negative
269200.0,"Concert Pharma Q3 EPS $(0.74) Down From $5.44 YoY, Sales $11K Down From $143.844M YoY",2018-11-01 07:08:00-04:00,CNCE,neutral
269201.0,UPDATE: Concert Pharma Amendment Provides For Added Patients To Be Entrolled To Evaluate 12 mg Dose Of CTP-543 Or Placebo Twice Daily For 24 Weeks,2018-09-26 07:03:00-04:00,CNCE,neutral
269202.0,Concert Pharma Reports Amendment Protocol Of Phase 2a Trial To Evaulate 12 mg Twice-Daily Dose Cohort CTP-453 For Treatment Of Alopecia Areata,2018-09-26 07:02:00-04:00,CNCE,neutral
269203.0,"Stocks Which Set New 52-Week Low Yesterday, September 17th",2018-09-18 09:27:00-04:00,CNCE,negative
269204.0,"Stocks Which Set New 52-Week Low Friday, September 14",2018-09-17 09:30:00-04:00,CNCE,negative
269205.0,"Stocks Which Set New 52-Week Low Yesterday, September 13th",2018-09-14 09:30:00-04:00,CNCE,negative
269206.0,"The Daily Biotech Pulse: FDA Nod For STAAR, Supernus Opens Wallet, Principia Biopharma To Debut",2018-09-14 08:38:00-04:00,CNCE,neutral
269207.0,Janney Capital Initiates Coverage On Concert Pharmaceuticals with Neutral Rating,2018-09-13 09:21:00-04:00,CNCE,neutral
269208.0,"Stocks Which Set New 52-Week Low Yesterday, September 11th",2018-09-12 15:29:00-04:00,CNCE,negative
269209.0,"Concert Pharmaceuticals Q2 EPS $(0.57) Beats $(0.62) Estimate, Sales $2K Miss $10K Estimate",2018-08-02 07:22:00-04:00,CNCE,negative
269210.0,Concert Pharmaceuticals Q1 EPS $(0.19) Beats $(0.58) Estimate,2018-05-03 07:38:00-04:00,CNCE,neutral
269211.0,Concert Pharmaceuticals Completes Enrollment in Phase 2a Trial of CTP-543 in Alopecia Areata,2018-04-25 07:09:00-04:00,CNCE,neutral
269212.0,34 Biggest Movers From Yesterday,2018-04-06 04:21:00-04:00,CNCE,neutral
269213.0,41 Biggest Movers From Yesterday,2018-04-03 04:18:00-04:00,CNCE,neutral
269214.0,44 Biggest Movers From Friday,2018-03-12 04:59:00-04:00,CNCE,neutral
269215.0,36 Stocks Moving In Friday's Mid-Day Session,2018-03-09 12:41:00-05:00,CNCE,neutral
269216.0,"Benzinga's Top Upgrades, Downgrades For March 9, 2018",2018-03-09 09:29:00-05:00,CNCE,positive
269217.0,Mizuho Upgrades Concert Pharmaceuticals to Buy from Neutral; Raises PT to $27 from $23,2018-03-09 04:22:00-05:00,CNCE,neutral
269218.0,45 Biggest Movers From Yesterday,2018-03-02 05:03:00-05:00,CNCE,neutral
269219.0,34 Stocks Moving In Thursday's Mid-Day Session,2018-03-01 12:43:00-05:00,CNCE,neutral
269220.0,Concert Pharmaceuticals Reports Q4 EPS $(0.26) vs $(0.43) Est.,2018-03-01 07:10:00-05:00,CNCE,neutral
269221.0,Concert Pharmaceuticals Announces Initiation of Enrollment in Second Cohort of CTP-543 Phase 2a Trial for Alopecia Areata,2018-02-12 07:07:00-05:00,CNCE,neutral
269222.0,38 Biggest Movers From Friday,2018-01-16 05:26:00-05:00,CNCE,neutral
269223.0,Mid-Afternoon Market Update: Tuniu Gains After Announcing $100M Share Repurchase Program; Aradigm Shares Slide,2018-01-12 14:32:00-05:00,CNCE,positive
269224.0,Concert Pharma Drops On Patent Litigation Setback; Mizuho Downgrades,2018-01-12 13:48:00-05:00,CNCE,negative
269225.0,Concert Pharma Shares Down 26.56% Despite Earlier FDA Grant Of Fast Track Designation For CTP-543; Mizuho Downgraded Shares To Neutral Citing Patent Board Decision Not To Grant Company A Post Grant Review In Litigation With Incyte Over CTP-543,2018-01-12 12:41:00-05:00,CNCE,negative
269226.0,33 Stocks Moving In Friday's Mid-Day Session,2018-01-12 12:25:00-05:00,CNCE,neutral
269227.0,Mid-Day Market Update: Dow Surges Over 200 Points; AquaBounty Technologies Shares Plummet,2018-01-12 12:03:00-05:00,CNCE,positive
269228.0,22 Stocks Moving In Friday's Pre-Market Session,2018-01-12 08:05:00-05:00,CNCE,neutral
269229.0,Concert Pharma Granted Fast Track Designation for CTP-543 for the Treatment of Alopecia Areata,2018-01-12 07:05:00-05:00,CNCE,positive
269230.0,UPDATE: Concert Pharmaceuticals Shares Up 8.42%; Earlier UBS Rasied Price Target From $22 to $34 Citing Strength Of Clinical Candidates And Underestimated Probability Of Success For CTP-543 Treatment,2017-12-19 12:48:00-05:00,CNCE,positive
269231.0,"Concert Pharmaceuticals Shares Up 8.71%; Hearing UBS Raised Price Target To $34 Today, As Yet Unconfirmed",2017-12-19 12:42:00-05:00,CNCE,positive
269232.0,Concert Pharmaceuticals Names Marc Becker CFO,2017-12-18 07:00:00-05:00,CNCE,neutral
269233.0,Concert Pharma Announces it Will Be Added to NASDAQ Biotechnology Index,2017-12-13 07:05:00-05:00,CNCE,neutral
269234.0,"Concert Pharmaceuticals Reports Q3 EPS $5.61 vs $(0.51) In Prior Year Period,  Sales $143.84M",2017-11-09 07:04:00-05:00,CNCE,neutral
269235.0,"Benzinga's Top Upgrades, Downgrades For October 26, 2017",2017-10-26 09:13:00-04:00,CNCE,positive
269236.0,"Mizuho Initiates Coverage On Concert Pharmaceuticals with Buy Rating, Announces $23.00 Price Target",2017-10-26 06:00:00-04:00,CNCE,neutral
269237.0,Concert Pharmaceuticals Shares Up 11.49% On High Volume; Late Monday BVF Partners Disclosed Purchase Of 331.916K Shares At $15.8375 In Form 4,2017-10-24 11:05:00-04:00,CNCE,positive
269238.0,38 Biggest Movers From Yesterday,2017-10-20 06:21:00-04:00,CNCE,neutral
269239.0,Concert Pharma Reports PTAB Has Denied Incyte Petition Challenging CTP-543 Patent,2017-10-19 13:01:00-04:00,CNCE,negative
269240.0,"Wells Fargo Healthcare Conference Concludes Today, Presenters Include: Foundation Medicine, Tenet Healthcare, bluebird bio, Envision Healthcare, Ironwood Pharmaceuticals, Quorum Health, and Concert Pharmaceuticals",2017-09-07 08:58:00-04:00,CNCE,positive
269241.0,18 Biggest Mid-Day Gainers For Monday,2017-07-24 12:24:00-04:00,CNCE,neutral
269242.0,"Concert Pharma Shares Rally Over $15 Level Following New Buy Rating, $20 Price Target",2017-07-24 11:55:00-04:00,CNCE,positive
269243.0,"Benzinga's Top Upgrades, Downgrades For July 24, 2017",2017-07-24 09:26:00-04:00,CNCE,positive
269244.0,"H.C. Wainwright Initiates Coverage On Concert Pharmaceuticals with Buy Rating, Announces $20.00 Price Target",2017-07-24 07:08:00-04:00,CNCE,neutral
269245.0,Concert Pharma Announces Termination of the HSR Act Waiting Period for CTP-656 Asset Purchase Agreement with Vertex,2017-07-24 07:02:00-04:00,CNCE,positive
269246.0,Concert Pharma Gets Clinical Hold on CTP-543 Lifted,2017-07-10 07:30:00-04:00,CNCE,neutral
269248.0,Concert Pharma Receives $30M of Venture Debt Financing from Hercules Capital,2017-06-12 07:06:00-04:00,CNCE,negative
269249.0,Concert Pharma CFO to Step Down and Return to Investment Banking,2017-05-30 07:05:00-04:00,CNCE,neutral
269250.0,Concert Pharma Reports Shareholder Approval of CTP-656 Asset Purchase Deal with Vertex,2017-05-24 10:02:00-04:00,CNCE,positive
269251.0,Concert Pharmaceuticals Receives Second Request from FTC for the Acquisition of CTP-656 from Vertex Pharma,2017-05-22 07:04:00-04:00,CNCE,neutral
269252.0,"UPDATE: Concert Says FDA Requested Review of Recently Completed Non-Clinical Studies, Did Not Cite a Safety Concern",2017-05-17 07:31:00-04:00,CNCE,negative
269253.0,Concert Pharma Reports Clinical Hold on Phase 2a Trial for CTP-543,2017-05-17 07:30:00-04:00,CNCE,neutral
269254.0,Concert Pharma Shares Halted News Pending,2017-05-17 07:25:00-04:00,CNCE,positive
269255.0,Concert Pharmaceuticals Reports Q1 EPS $(0.60) vs $(0.63) In Prior Year Period,2017-05-02 07:50:00-04:00,CNCE,neutral
269256.0,"UPDATE: Concert Pharma Cites 'a late emerging clinical tablet appearance issue' for CTP-543 Delay; Sees Initiating, Enrolling Trial in '17, Topline Data in Q1'18",2017-04-05 08:22:00-04:00,CNCE,negative
269257.0,8-K from Concert Pharma Shows News of Unexpected Delay in Initiation of CTP-543 Phase 2a Trial for Alopecia Areata,2017-04-05 08:21:00-04:00,CNCE,negative
269258.0,Wall Street's M&A Chatter From March 6,2017-03-07 07:10:00-05:00,CNCE,neutral
269259.0,Mid-Afternoon Market Update: GoPro Slides Following Goldman Sachs Downgrade; TG Therapeutics Shares Spike Higher,2017-03-06 14:33:00-05:00,CNCE,positive
269260.0,15 Biggest Mid-Day Gainers For Monday,2017-03-06 12:56:00-05:00,CNCE,neutral
269261.0,Mid-Day Market Update: Dow Falls 80 Points; Concert Pharma Shares Spike Higher,2017-03-06 12:18:00-05:00,CNCE,positive
269262.0,Mid-Morning Market Update: Markets Open Lower; Deutsche Bank Plans to Raise Capital,2017-03-06 10:07:00-05:00,CNCE,negative
269263.0,Q4 2016 Real-Time Call Brief,2017-03-06 09:15:00-05:00,CNCE,neutral
269264.0,20 Stocks Moving In Monday's Pre-Market Session,2017-03-06 08:10:00-05:00,CNCE,neutral
269265.0,"Concert Pharma Shares Resume Trade, Now Up 14%",2017-03-06 07:45:00-05:00,CNCE,positive
269266.0,A Peek Into The Markets: U.S. Stock Futures Edge Lower Ahead Of Factory Orders Data,2017-03-06 07:42:00-05:00,CNCE,negative
269267.0,Concert Pharma Shares to Resume Trade at 7:45 a.m. EST,2017-03-06 07:18:00-05:00,CNCE,positive
269268.0,"Concert Pharmaceuticals Reports Q4 EPS $(0.54) vs. $(0.61) Est., Sales $21K",2017-03-06 07:15:00-05:00,CNCE,neutral
269269.0,Vertex to Acquire CTP-656 from Concert Pharmaceuticals For $160M Cash And Potential $90M In Milestones,2017-03-06 07:00:00-05:00,CNCE,neutral
269270.0,TG Therapeutics and Concert Pharma Halted,2017-03-06 06:59:00-05:00,CNCE,neutral
269271.0,Concert Pharmaceuticals Presents Favorable CTP-543 Phase 1 Results at American Academy of Dermatology Annual Meeting,2017-03-05 13:03:00-05:00,CNCE,positive
269272.0,Concert Pharma Reports Received FDA Orphan Drug Designation for CTP-656 for Treatment of Cystic Fibrosis,2017-01-20 08:30:00-05:00,CNCE,neutral
269273.0,12 Biggest Mid-Day Losers For Tuesday,2017-01-17 12:53:00-05:00,CNCE,negative
269274.0,Concert Pharmaceuticals Provides Details on CTP-656 Development in U.S. and Europe,2017-01-17 07:02:00-05:00,CNCE,neutral
269275.0,Concert Pharmaceuticals Begins Phase 2 Clinical Trial Evaluating CTP-656 for the Treatment of Cystic Fibrosis,2016-12-21 07:30:00-05:00,CNCE,neutral
269276.0,"Concert Pharmaceuticals Announces CTP-543 Positive Top-Line Phase 1 Results, CTP-543 to Advance into Phase 2 in First Quarter of 2017",2016-12-14 07:30:00-05:00,CNCE,positive
269277.0,"Concert Pharma Reports Q3 EPS $(0.51) vs $(0.63) Est., Sales $26K vs $420K Est.",2016-11-08 07:14:00-05:00,CNCE,neutral
269278.0,7 Stocks Which Plummeted Three Days On Increasing Volume,2016-09-30 10:00:00-04:00,CNCE,neutral
269279.0,"25 Stocks Which Rallied Four Days, Then Sold Off Yesterday",2016-09-22 09:47:00-04:00,CNCE,neutral
269280.0,"Concert Pharma Reports Q2 EPS $(0.60) vs $(0.63) Est., Sales $71K vs $30K Est.",2016-08-09 07:28:00-04:00,CNCE,neutral
269281.0,Stifel Nicolaus Initiates Coverage on Concert Pharmaceuticals at Buy,2016-07-01 07:10:00-04:00,CNCE,neutral
269282.0,Concert Pharmaceuticals IR Tells Benzinga There is No News from the Co,2016-06-20 11:56:00-04:00,CNCE,negative
269283.0,"Concert Pharma Shares Resume Trade, Touch Fresh Session Low at $10.20, Now Up ~$0.50 from Low Tick",2016-06-20 11:43:00-04:00,CNCE,positive
269284.0,Concert Pharma Shares Plunge Into Negative Territory; Halted on Circuit Breaker Down ~7.5%,2016-06-20 11:38:00-04:00,CNCE,negative
269285.0,"Concert Pharmaceuticals Presents CTP-656 Phase 1 Results at European Cystic Fibrosis Conference , Concert Pharmaceuticals Presents CTP-656 Phase 1 Results at European Cystic Fibrosis Conference",2016-06-10 10:30:00-04:00,CNCE,neutral
269286.0,Concert Pharma Reports Initiation of Phase 1 Trial of CTP-543 as New Treatment for Alopecia Areata,2016-05-19 07:01:00-04:00,CNCE,neutral
269287.0,Concert Pharmaceuticals Reports Q1 EPS $(0.63) vs. Est. $(0.45),2016-05-05 07:25:00-04:00,CNCE,neutral
269288.0,Concert Pharmaceuticals Reports  Positive Data from Multiple Dose Phase 1 Clinical Trial of CTP-656 For Cystic Fibrosis Treatment,2016-04-28 16:31:00-04:00,CNCE,positive
269289.0,"Concert Pharmaceuticals Reports Q4 EPS $0.03 vs. Est. $(0.05), Rev. $10.3M vs. Est. $11.24M",2016-03-01 07:00:00-05:00,CNCE,neutral
269290.0,Concert Pharma Says CTP-656 Phase 1 Results Superior to Kalydeco,2016-02-29 16:11:00-05:00,CNCE,positive
269291.0,Concert Pharmaceuticals Initiates Phase 1 Multiple Ascending Dose Trial with CTP-656 for Cystic Fibrosis,2015-11-12 07:05:00-05:00,CNCE,neutral
269292.0,"Concert Pharmaceuticals Reports Q3 EPS $(0.39) vs. Est. $(0.31), Rev. $1.709M vs. Est. $4.5M",2015-11-05 07:10:00-05:00,CNCE,neutral
269293.0,Concert Pharmaceuticals Highlights CTP-656 Phase 1 Results at North American Cystic Fibrosis Conference,2015-10-08 14:53:00-04:00,CNCE,neutral
269294.0,Concert Pharmaceuticals Announces $8 Million Milestone from Celgene,2015-10-08 07:02:00-04:00,CNCE,neutral
269295.0,Concert Pharmaceuticals Volatile Following Report of Results of a Phase 1 Trial of CTP-656,2015-09-22 11:08:00-04:00,CNCE,neutral
269296.0,Concert Pharmaceuticals Reports Results of a Phase 1 Trial That Shows CTP-656 Achieved a Superior Pharmacokinetic Profile to Kalydeco,2015-09-22 11:00:00-04:00,CNCE,positive
269297.0,Benzinga's Top Initiations,2015-08-12 09:58:00-04:00,CNCE,positive
269298.0,"Brean Capital Initiates Coverage on Concert Pharmaceuticals at Buy, Announces $21.00 PT",2015-08-12 06:19:00-04:00,CNCE,neutral
269299.0,"Concert Pharmaceuticals Reports Q2 EPS $1.80 vs. Est. $(0.46) May Not Compare, Rev. $53.409M",2015-08-05 07:01:00-04:00,CNCE,neutral
269300.0,Concert Pharmaceuticals Receives $50M Payment from Auspex Pharmaceuticals,2015-06-08 07:00:00-04:00,CNCE,neutral
269301.0,"Flagship Ventures Forms Strategic Innovation Partnerships with AstraZeneca, Nestle Health Science and Bayer CropScience",2015-05-05 07:17:00-04:00,CNCE,positive
269302.0,"Zachary Prensky @Zackfoot Tweet: $CNCE now my biggest position, bout LT and a trading block",2015-03-30 10:41:00-04:00,CNCE,negative
269303.0,Morning Market Losers,2015-03-19 10:12:00-04:00,CNCE,negative
269304.0,"Concert Pharmaceuticals Announces Pricing of Public Offering, 3.3M Shares At $15.15/Share",2015-03-19 09:00:00-04:00,CNCE,positive
269305.0,Benzinga's Top #PreMarket Losers,2015-03-19 08:20:00-04:00,CNCE,negative
269306.0,Concert Pharma Begins Phase 1 Deuterated Ivacaftor Evaluation For Cystic Fibrosis,2015-03-12 07:11:00-04:00,CNCE,neutral
269307.0,Concert Pharmaceuticals Names James V. Cassella as Chief Development Officer,2015-02-04 07:08:00-05:00,CNCE,neutral
269308.0,"Jazz Pharma, Concert Pharma Report JZP-386 Program Update",2014-12-09 08:30:00-05:00,CNCE,neutral
269309.0,"Concert Pharmaceuticals Presents Positive Data From Multiple Dose Phase 1 Clinical Trial of CTP-354, Lead Candidate For The Treatment of Spasticity",2014-10-13 07:07:00-04:00,CNCE,positive
269310.0,US Stock Futures Flat; All Eyes On FOMC Decision,2014-09-17 07:19:00-04:00,CNCE,neutral
269311.0,Concert Pharmaceuticals Initiates CTP-730 Phase 1 Clinical Trial Under Celgene Collaboration ,2014-09-17 07:04:00-04:00,CNCE,neutral
269312.0,Concert Pharma Reports Q2 EPS of $(0.45) vs $(0.42) Est; Revenue of $1.24M vs $1.30M Est,2014-08-12 07:01:00-04:00,CNCE,neutral
269313.0,Concert Pharma Announces Completed Steps To Lift Clinical Hold,2014-07-16 07:02:00-04:00,CNCE,neutral
269314.0,Concert Pharma Announces Successful End of Phase 2,2014-07-08 07:01:00-04:00,CNCE,positive
269315.0,"Ladenburg Thalmann Initiates Coverage on Concert Pharma at Buy, Announces $24.00 PT",2014-06-26 07:48:00-04:00,CNCE,neutral
269316.0,"Morning Market Movers Friday, May 23, 2014",2014-05-23 10:44:00-04:00,CNCE,neutral
269317.0,Concert Pharma Reports Q1 EPS of $(0.76) vs $(0.49) Est,2014-05-14 07:01:00-04:00,CNCE,neutral
269318.0,"UPDATE: Concert Pharamceuticals Says Primary Endpoint of the Trial was Change after 24 Weeks in UACR, Trial did Not Meet this Endpoint, at 48 Weeks",2014-04-25 14:06:00-04:00,CNCE,neutral
269319.0,Concert Pharmaceuticals Presents Positive 48-Week Results from Phase 2 Clinical Trial of CTP-499,2014-04-25 14:01:00-04:00,CNCE,positive
269320.0,"Roth Capital Initiates Coverage on Concert Pharma at Buy, Announces $28.00 PT",2014-03-19 09:13:00-04:00,CNCE,neutral
269321.0,"Perion Network,	 Horizon Pharma, Manitex, Attunity, Galena Biopharma, Concert Pharmaceuticals, Spansion, Magellan Petroleum,	JAKKS Pacific Presenting at Roth Conference at 12:00 PM ET",2014-03-10 12:08:00-04:00,CNCE,neutral
269322.0,Benzinga's Top Initiations,2014-03-10 08:41:00-04:00,CNCE,positive
269323.0,"UBS Initiates Coverage on Concert Pharma at Buy, Announces $25.00 PT",2014-03-10 08:16:00-04:00,CNCE,neutral
269324.0,Wells Fargo Initiates Coverage on Concert Pharma at Outperform,2014-03-10 08:15:00-04:00,CNCE,positive
269325.0,"JMP Initiates Coverage on Concert Pharma at Market Outperform, Announces $28.00 PT",2014-03-10 08:15:00-04:00,CNCE,neutral
269326.0,"UBS Initiates Coverage on Concert Pharma at Buy, Announces $25.00 PT",2014-03-10 07:34:00-04:00,CNCE,neutral
269327.0,Shares of Concert Pharma Open for Trade at $15.75 After Pricing at $14/Share,2014-02-13 10:55:00-05:00,CNCE,positive
269328.0,"Waiting on IPOs for Amedica (AMDA), Concert Pharma (CNCE)",2014-02-13 09:59:00-05:00,CNCE,neutral
269329.0,"Concert Pharma Files $74.8M IPO, Will List on NASDAQ Under 'CNCE'",2014-01-13 17:03:00-05:00,CNCE,neutral
